Doxorubicin liposomal - ALZA

Drug Profile

Doxorubicin liposomal - ALZA

Alternative Names: Caelyx; Dox-SL; Doxil; JNS-002; Liposomal doxorubicin - ALZA; Pegylated liposomal doxorubicin; SPI 49

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ALZA Corporation
  • Developer Janssen Biotech; University of Kansas Medical Center; Xian-Janssen
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Kaposi's sarcoma; Multiple myeloma; Ovarian cancer

Most Recent Events

  • 01 Sep 2016 Schering-Plough in collaboration with SOLTI Breast Cancer Research Group completes a phase II trial for Breast cancer in Spain (NCT00563953)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Japan (IV)
  • 27 Apr 2016 NICE recommends pegylated liposomal doxorubicin hydrochloride as an option for recurrent ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top